Stock listing

Stuttgart:2CL BridgeBio Pharma, Inc. Aktie

German listing (Stuttgart) of BridgeBio Pharma, Inc. · home listing NASDAQ:BBIO

Follow BridgeBio Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BBIO

$76.03 USD -1.98 (-2.5%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BBIO

Past year +17.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$75.46 – $78.22 USDNov 20, 2026
Volume
1.48M sharesNov 20, 2026
Market cap
$14.86B USDAt the close on Nov 20, 2026 · price × 195.5M shares outstanding
52-week range
$62.50 – $93.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$188.8M USDMedian day 2.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BridgeBio Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BBIO · Home$76.03 USD-1.98 (-2.5%)1,478,712$77.85$78.22$75.46$78.01Close on Nov 20, 2026
Frankfurt:2CL€70.31 EUR-1.10 (-1.5%)—€69.98€70.31€69.98€71.41Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$76.03-1.98-2.5%$77.85$78.22$75.461,478,712
$78.01+1.21+1.6%$76.45$78.25$75.993,547,072
$76.80-0.56-0.7%$76.74$77.10$74.752,812,198
$77.36-0.94-1.2%$79.00$79.13$76.951,347,322
$78.30+0.13+0.2%$78.60$79.13$77.581,149,255
$78.17-1.37-1.7%$79.00$80.82$78.001,804,089
$79.54+0.87+1.1%$78.86$79.74$77.802,324,843
$78.67+0.74+0.9%$76.60$79.83$76.603,284,441
$77.93+3.64+4.9%$74.58$78.06$73.493,000,166
$74.29+0.020.0%$74.21$75.67$73.193,157,576
$74.27-3.62-4.6%$77.90$78.58$74.113,383,543
$77.89+3.86+5.2%$75.15$78.00$73.525,551,823
$74.03-0.965-1.3%$75.48$76.79$73.952,478,768
$75.00+0.045+0.1%$75.01$76.70$74.203,095,469
$74.95+4.22+6.0%$72.85$75.65$71.915,770,977
$70.73-0.09-0.1%$71.37$73.02$70.214,933,383
$70.82+1.45+2.1%$68.79$71.18$68.653,111,389
$69.37+1.22+1.8%$68.25$69.64$68.002,041,947
$68.15-0.41-0.6%$68.56$68.82$67.892,059,129
$68.56+0.44+0.6%$67.69$68.86$67.022,403,443
$68.12+0.38+0.6%$67.48$69.32$67.072,780,421
$67.74+0.19+0.3%$68.04$68.79$67.553,008,801
$67.55-0.39-0.6%$68.28$69.00$67.252,732,829
$67.94+1.55+2.3%$67.35$68.52$66.732,292,327
$66.39-0.74-1.1%$67.03$67.04$65.262,055,500
$67.13+2.19+3.4%$65.67$67.76$65.442,638,800
$64.94+1.64+2.6%$63.34$65.36$62.862,700,500
$63.30-2.45-3.7%$66.05$66.05$62.942,709,000
$65.75+0.40+0.6%$65.35$66.42$65.201,778,900
$65.35+0.31+0.5%$65.04$65.94$64.341,846,500
$65.04-1.46-2.2%$66.39$66.41$63.703,362,000
$66.50-0.46-0.7%$66.78$67.59$66.152,064,400
$66.96+0.82+1.2%$67.75$68.12$65.713,709,900
$66.14-1.11-1.7%$67.40$68.08$65.462,168,500
$67.25+0.34+0.5%$67.10$68.68$66.232,646,100
$66.91+1.11+1.7%$65.72$67.26$65.163,549,900
$65.80-0.17-0.3%$66.14$67.32$65.612,822,400
$65.97-0.64-1.0%$66.38$67.16$65.823,596,900
$66.61+1.04+1.6%$65.07$67.34$64.362,969,300
$65.57-0.71-1.1%$66.50$67.07$64.842,090,200
$66.28+0.57+0.9%$65.85$67.30$65.334,271,600
$65.71-3.52-5.1%$69.23$70.00$64.903,677,600
$69.23+2.65+4.0%$66.90$69.77$66.613,782,400
$66.58-0.030.0%$67.01$67.33$65.783,167,400
$66.61-0.70-1.0%$67.39$67.56$66.104,103,500
$67.31-0.99-1.4%$69.72$69.99$66.932,344,100
$68.30-0.09-0.1%$68.52$69.46$67.114,785,800
$68.39-3.99-5.5%$72.26$72.41$66.963,993,000
$72.38-0.06-0.1%$72.55$73.67$72.171,851,300
$72.44-0.06-0.1%$73.23$74.11$71.981,766,600
$72.50-3.58-4.7%$75.27$75.50$72.123,064,100
$76.08+1.32+1.8%$73.63$76.81$73.472,307,000
$74.76-0.08-0.1%$73.60$76.34$73.262,094,500
$74.84-0.57-0.8%$74.98$75.37$74.111,539,400
$75.41-1.09-1.4%$76.43$76.64$75.201,098,000
$76.50-0.07-0.1%$76.60$78.25$75.961,620,600
$76.57-0.020.0%$76.61$77.45$76.221,448,500
$76.59-0.010.0%$76.20$77.24$75.022,063,600
$76.60-2.08-2.6%$79.99$80.55$76.341,922,100
$78.68-0.69-0.9%$79.25$79.73$78.341,033,800
$79.37-1.03-1.3%$79.75$80.76$79.331,705,000
$80.40-0.67-0.8%$81.89$82.50$80.201,469,328
$81.07-0.43-0.5%$80.98$81.68$80.161,113,409
$81.50-1.44-1.7%$82.89$83.37$81.361,743,900
$82.94-1.01-1.2%$83.51$84.37$82.632,030,600
Ticker
Stuttgart:2CL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All BridgeBio Pharma, Inc. news

BridgeBio Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
56 in the last 12 months · 275 in all · newest Nov 17, 2026 · oldest 2019
Calls
7 calls with a replay · 7 with a transcript · latest Oct 29, 2026
Decks
41 decks · latest May 7, 2026

Where BridgeBio Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BBIO · Home listingNASDAQUnited StatesUSD
gettex:2CLgettexGermanyEUR
LS Exchange:A2PLX7LS ExchangeGermanyEUR
Tradegate:2CLTradegateGermanyEUR
Lang & Schwarz:A2PLX7Lang & SchwarzGermanyEUR
BX Swiss:BBIOBX SwissSwitzerlandCHF
Milan:1BBIOMilanItalyEUR
BOATS:BBIOBOATSUnited StatesUSD
Frankfurt:2CLFrankfurtGermanyEUR
Dusseldorf:2CLDusseldorfGermanyEUR
Hamburg:2CLHamburgGermanyEUR
Munich:2CLMunichGermanyEUR
Stuttgart:2CL · This pageStuttgartGermanyEUR
BMV:BBIOBMVMexicoMXN
Hanover:2CLHanoverGermanyEUR
Xetra:2CLXetraGermanyEUR

Valuation

EV/sales 16.9× against a median of 9.0×: 7th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$15.95B USD
P/E
Loss
EV/sales
16.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
94.3%
Operating margin
−38.5%
Net margin
−59.8%
Debt to equity
Negative equity
Beta vs S&P 500
0.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BridgeBio Pharma, Inc. · NASDAQ:BBIOUS$14.86BUS$15.95Bn/a16.9×n/an/a−59.8%n/a0.89
Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNYUS$19.26BUS$15.68B7.3×n/an/a5.3×n/a0.0×0.58
Ascendis Pharma A/S · NASDAQ:ASNDUS$16.73BUS$16.15B17.1×12.2×61.1×10.0×73.5%0.3×0.49
Exelixis, Inc. · NASDAQ:EXELUS$15.77BUS$14.88B17.8×6.0×n/a8.6×35.4%0.0×0.69
Neurocrine Biosciences, Inc. · NASDAQ:NBIXUS$15.24BUS$14.50B21.7×3.9×n/a3.9×19.0%0.0×0.79
PharmaEssentia Corp. · TWSE:6446US$15.10BUS$14.39B65.3×22.9×56.4×13.5×36.8%0.0×n/a
BioMarin Pharmaceutical Inc. · NASDAQ:BMRNUS$11.70BUS$15.14Bn/a4.1×81.2×1.9×−0.5%0.7×0.32
Financiere de Tubize S.A. · EURONEXT:TUBUS$11.08BUS$11.02B108×n/an/a5.1×n/a0.0×n/a
Halozyme Therapeutics, Inc. · NASDAQ:HALOUS$10.41BUS$12.59B21.5×7.0×18.2×n/a26.9%n/a0.63
Kymera Therapeutics, Inc. · NASDAQ:KYMRUS$9.84BUS$8.87Bn/a86.8×n/a6.1×−341.8%0.0×0.92
TG Therapeutics, Inc. · NASDAQ:TGTXUS$9.70BUS$9.94B91.4×11.1×51.5×16.9×11.8%1.3×0.70
Median of the othersUS$13.40BUS$14.45B21.6×9.0×56.4×6.1×22.9%0.0×0.66

Forecasts

14 strong buy · 5 buy · 3 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
106.85 USD · Analysts' mean
EPS, year to Dec 2026
-2.49 · 7 analysts
Revenue, year to Dec 2026
1.1B · 16 analysts

Team and board

Officers

OfficerRole
Pedro J. BeltranChief Executive Officer, Idan Elmelech as Chief Operating Officer
Natalie HenchcliffeCOO
Daniel NickleChief Legal Officer
Bubba MurarkaExecutive Vice President
Chinmay ShuklaSenior Vice President
Mandy RohrigVice President of Operations
Robert ChengExecutive Vice President
Alex FidelerExecutive Director
Brian KoertgenCTO
BridgeBio PharmaExecutive Chairman by the Board of Directors
Daniel Hong
Hassan JaroudiDirector of Finance
Kasia GosekChief Strategy Officer
Lilian ZhangDirector of Research
Reed Ashford
Scott YahiroChief Commercial Officer

Board

DirectorRole
Alex FidelerExecutive Director
ContactKaitlyn ReillyDirector
ContactKristen KelleherDirector
Daniel Hong
Jeffrey Clarke
Katherine Chang
Reed Ashford

Events

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · After close+6.0%
Q2 2026Aug 10, 2026 · After close−1.1%
Q1 2026May 7, 2026 · After close−0.1%
Q4 2025Feb 19, 2026−7.8%
Q3 2025Oct 29, 2025 · After close−4.9%
Q2 2025Aug 5, 2025 · After close−8.9%
Q1 2025Apr 30, 2025 · Before open+5.3%
Q4 2024Feb 20, 2025 · Before open+1.4%
Q3 2024Nov 1, 2024 · Before open+8.8%
Q2 2024Aug 1, 2024 · Before open+0.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+2.6%
Q4 2023Feb 22, 2024 · Before open−1.6%
Q3 2023Nov 2, 2023 · Before open+1.0%
Q2 2023Aug 3, 2023 · Before open+0.3%
Q1 2023May 4, 2023 · Before open−6.3%
Q4 2022Feb 23, 2023 · Before open−4.6%
Q3 2022Nov 3, 2022 · Before open−0.9%
Q2 2022Aug 4, 2022 · Before open+25.7%
Q1 2022May 5, 2022 · Before open−12.5%
Q4 2021Feb 24, 2022 · Before open+9.0%

Open Events

Decks

DeckKindSlidesDate
Q1 2026 Earnings PresentationEarnings41 slidesMay 7, 2026
Investor Presentation (February 2026)Investor deck92 slidesFeb 24, 2026
Q4 2025 Earnings PresentationEarnings93 slidesFeb 24, 2026
Technical Presentation (February 2026)Technical32 slidesFeb 12, 2026
Investor Presentation (January 2026)Investor deck83 slidesJan 12, 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference48 slidesJan 12, 2026
Investor Day (January 2026)Investor day36 slidesJan 9, 2026
Investor Presentation (October 2025)Investor deck71 slidesOct 29, 2025
Technical Presentation (October 2025)Technical29 slidesOct 29, 2025
Technical Presentation (October 2025)Technical27 slidesOct 27, 2025
All 41 decks
DeckKindSlidesDate
Technical Presentation (September 2025)Technical15 slidesSep 28, 2025
Investor Day (September 2025)Investor day30 slidesSep 10, 2025
Investor Presentation (August 2025)Investor deck55 slidesAug 5, 2025
Technical Presentation (August 2025)Technical8 slidesAugust 2025
Technical Presentation (July 2025)Technical16 slidesJul 14, 2025
Investor Day (July 2025)Investor day29 slidesJul 11, 2025
Investor Presentation (April 2025)Investor deck56 slidesApr 29, 2025
2025 NTSAD Family ConferenceConference14 slidesApr 25, 2025
J.P. Morgan Healthcare Conference 2025Conference35 slidesJan 13, 2025
Technical Presentation (September 2024)Technical18 slidesSep 30, 2024
Technical Presentation (September 2024)Technical20 slidesSeptember 2024
Technical Presentation (June 2024)Technical23 slidesJun 4, 2024
Technical Presentation (May 2024)Technical22 slidesMay 29, 2024
MENA Congress for Rare Diseases 2024Conference12 slidesMay 2024
J.P. Morgan Healthcare Conference 2024Conference25 slidesJan 8, 2024
Technical Presentation (October 2023)Technical12 slidesOctober 2023
Technical Presentation (September 2023)Technical13 slidesSep 20, 2023
Technical Presentation (September 2023)Technical11 slidesSep 12, 2023
Technical Presentation (July 2023)Technical21 slidesJul 17, 2023
Technical Presentation (June 2023)Technical16 slidesJun 17, 2023
ENDO 2023 Annual MeetingConference5 slidesJune 2023
Technical Presentation (March 2023)Technical23 slidesMar 6, 2023
Technical Presentation (February 2023)Technical15 slidesFeb 16, 2023
Technical Presentation (June 2022)Technical25 slidesJun 13, 2022
Technical Presentation (June 2022)Technical12 slidesJun 9, 2022
Technical Presentation (December 2021)Technical15 slidesDec 27, 2021
Investor Day (October 2021)Investor day112 slidesOct 12, 2021
Investor Presentation (June 2021)Investor deck52 slidesJun 1, 2021
Investor Presentation (March 2021)Investor deck28 slidesMar 22, 2021
Merger or Acquisition (October 2020)Merger or acquisition12 slidesOct 5, 2020
Investor Day (September 2020)Investor day24 slidesSep 29, 2020

Open Decks

Financings

RaiseDate
Preferred equity
Closed: US$1B raised
Buyers: Sixth Street (led the financing); HealthCare Royalty
Use of proceeds: Fund three potential upcoming launches while continuing to invest in indication expansion across the pipeline
Aug 10, 2026
Series A Cumulative Convertible Participating Preferred Stock
Closed: convertible
Buyers: Sixth Street (funded $800M as the lead investor); HealthCare Royalty (funded $133.9M)
Use of proceeds: Strengthen the balance sheet and allocate capital across its highest return opportunities, including product launches
Jul 1, 2026
0.75% convertible senior notes due 2033
Update: US$550M
Use of proceeds: Repurchase, settle conversions of or repay part of the 2.50% convertible notes due 2027, and general corporate purposes
Jan 15, 2026
1.75% convertible senior notes due 2031
Update: US$500M
Use of proceeds: Repay and terminate the Blue Owl Financing Agreement, repurchase about $48.3 million of common stock, and general corporate purposes
Feb 25, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Jun 26, 2019.

Price
US$17.00 a share
Shares offered
20,500,000 shares of common stock
Offering size
US$348.5 million
Underwriters' option
Up to 3,075,000 more shares
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets, Raymond James · In the order on the cover
Shares delivered
On or about Jul 1, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 14, 2019
Filed publiclyMay 24, 2019
Amended 4 timesNewest Jun 26, 2019
Shares registered with an exchangeJun 26, 2019
Declared effective by the SECJun 26, 2019
Final prospectus, with the priceJun 28, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue502.1M221.9M9.30M77.6M69.7M8.25M40.6M
Cost of revenue21.0M3.88M2.45M3.43M3.11M
Gross profit481.1M218.0M6.86M74.2M66.6M
Research and development452.0M506.5M455.7M399.5M451.0M337.0M209.9M140.1M30.6M
Selling, general and administrative531.2M288.9M150.6M143.2M192.2M145.7M94.4M
Operating income-523.4M-593.0M-607.4M-512.2M-576.6M-474.5M-266.2M-183.7M-43.9M
Depreciation and amortization5.43M6.08M6.49M6.77M5.84M1.46M859.0K
EBITDA-518.0M-586.9M-600.9M-505.4M-570.8M-473.0M-265.4M
Interest expense53.1M91.0M81.3M80.4M46.8M36.7M8.77M2.55M13.0K
Income before tax-732.5M-542.2M-653.3M-484.7M-586.5M505.5M288.6M169.5M43.8M
Income tax435.0K1.15M00
Net income-724.9M-535.8M-643.2M-481.2M-562.5M-448.7M-260.6M-130.7M-30.6M
Earnings per share, basic-3.78-2.88-3.95-3.26-3.90-3.80-2.48-2.12-1.00
Earnings per share, diluted-3.78-2.88-3.95-3.26-3.90-3.80-2.48-2.12-1.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents570.1M681.1M375.9M376.7M393.8M356.1M363.8M436.1M92.0M
Short-term investments17.4M0051.6M393.7M251.0M182.2M
Receivables139.4M4.72M1.75M
Inventory26.8M0
Current assets797.7M720.7M477.6M548.9M888.9M642.8M568.6M445.2M
Property, plant and equipment5.37M7.01M11.8M14.6M30.1M20.3M5.63M1.57M
Total assets936.0M919.3M546.4M623.0M1.01B703.6M631.7M464.9M
Accounts payable36.2M9.62M10.7M11.6M11.9M8.95M8.85M13.5M
Current liabilities288.0M154.4M143.8M121.4M135.1M95.6M60.4M32.6M
Long-term debt437.3M446.4M431.0M430.8M92.4M91.8M54.5M
Total debt2.01B437.3M446.4M431.0M430.8M93.9M95.4M54.5M
Total liabilities3.01B2.38B1.89B1.87B1.88B595.7M155.7M87.6M
Shareholders' equity-2.09B-1.47B-1.35B-1.25B-870.4M57.9M408.5M314.9M85.9M
Shares outstanding194.8M190.0M175.1M150.6M147.3M122.8M123.7M92.1M123.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-445.9M-520.7M-527.7M-419.5M-497.9M-399.7M-253.6M-136.6M-40.5M
Capital spending-1.10M-933.0K-1.31M-4.82M-13.2M-7.52M-2.64M-2.18M-464.0K
Free cash flow-447.0M-521.7M-529.0M-424.3M-511.2M-407.2M-256.2M-138.8M-41.0M
Cash from investing-24.5M60.8M54.0M453.1M-200.8M-53.0M-217.3M-21.0M-464.0K
Cash from financing359.3M748.5M451.5M-13.1M736.4M447.2M398.8M501.5M113.0M
Dividends paid-997.0K-1.15M
Share buybacks-48.3M000-200.0M-75.0M
Change in cash-111.1M288.5M-22.2M20.5M37.7M-5.52M-72.0M343.9M72.0M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Current reportSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
8-K · Current reportAug 31, 2026Current reportSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 17, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
8-K · Current reportAug 17, 2026Material contractSEC
424B7 · ProspectusAug 14, 2026Offer documentSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
S-3ASR · Registration statementJul 24, 2026Offer documentSEC
S-8 · Registration statement for employee plansJul 24, 2026Offer documentSEC
8-K · Current reportJul 22, 2026Current reportSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 10, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
8-K · Current reportJul 2, 2026Material contractSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 29, 2026Big-stake noticeSEC
8-K · Current reportMay 27, 2026Current reportSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026Current reportSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
8-K · Current reportMay 8, 2026Material contractSEC
S-3ASR · Registration statementMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 16, 2026Big-stake noticeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
144 · Notice of proposed saleApr 9, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
144 · Notice of proposed saleMar 13, 2026Other filingsSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
144 · Notice of proposed saleMar 10, 2026Other filingsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
8-K · Current reportFeb 12, 2026Current reportSEC
8-K · Current reportJan 21, 2026Material contractSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
144 · Notice of proposed saleNov 6, 2025Other filingsSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
144 · Notice of proposed saleOct 29, 2025Other filingsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
10-Q · Quarterly reportOct 29, 2025Quarterly reportSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportOct 29, 2025ResultsSEC
8-K · Current reportOct 27, 2025Current reportSEC
144 · Notice of proposed saleOct 27, 2025Other filingsSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
144 · Notice of proposed saleSep 5, 2025Other filingsSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
144 · Notice of proposed saleAug 21, 2025Other filingsSEC
144 · Notice of proposed saleAug 20, 2025Other filingsSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
144 · Notice of proposed saleAug 11, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
S-8 · Registration statement for employee plansAug 5, 2025Offer documentSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
144 · Notice of proposed saleAug 5, 2025Other filingsSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 1, 2025Big-stake noticeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Material contractSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 30, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 26, 2025Other filingsSEC
144 · Notice of proposed saleJun 26, 2025Other filingsSEC
144 · Notice of proposed saleJun 26, 2025Other filingsSEC
144 · Notice of proposed saleJun 26, 2025Other filingsSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC

This page holds 200 of 840 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BridgeBio Pharma, Inc.’s releases · as of Nov 5, 2026

Common shares
195,492,997
Fully diluted
195,640,575

Fully diluted

LineSharesAs of
Common shares195,492,997
Options and RSUs147,578Nov 5, 2026

Warrants and options

Lot
RSUs · expiry not stated

Share count over time

CountShares
Nov 22, 2026195,492,997

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard16.8M8.6%US$1.11BSep 30, 2026
Janus Henderson14.6M7.5%US$958MSep 30, 2026
Farallon Capital Management, L.L.C.14.2M7.3%US$937MSep 30, 2026
BlackRock10.4M5.3%US$684MSep 30, 2026
Viking Global Investors LP9.79M5.0%US$644MSep 30, 2026
Wellington9.46M4.9%US$622MSep 30, 2026
Kohlberg Kravis Roberts & Co. L.P.8.26M4.2%US$544MSep 30, 2026
State Street4.98M2.6%US$327MSep 30, 2026
Invesco4.32M2.2%US$284MSep 30, 2026
Franklin Templeton4.15M2.1%US$313MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
JPMorgan4M2.1%US$264MSep 30, 2026
Two Sigma3.66M1.9%US$241MSep 30, 2026
Geode Capital3.28M1.7%US$216MSep 30, 2026
Aisling Capital Management LP3.09M1.6%US$203MSep 30, 2026
UBS3.04M1.6%US$200MSep 30, 2026
Adage Capital Partners Gp, L.L.C.3.03M1.6%US$200MSep 30, 2026
Paradigm Biocapital Advisors LP2.35M1.2%US$154MSep 30, 2026
D. E. Shaw & Co., Inc.2.22M1.1%US$146MSep 30, 2026
Polar Capital Holdings Plc2.15M1.1%US$142MSep 30, 2026
Manufacturers Life Insurance Company, The1.95M1.0%US$128MSep 30, 2026
Sc US (Ttgp), LTD.1.86M0.96%US$122MSep 30, 2026
T. Rowe Price1.74M0.90%US$115MSep 30, 2026
Citadel1.73M0.89%US$114MSep 30, 2026
Primecap Management Co1.7M0.87%US$112MSep 30, 2026
Pictet Asset Management Holding SA1.69M0.87%US$111MSep 30, 2026
Citigroup Inc1.68M0.86%US$110MSep 30, 2026
Fidelity1.67M0.86%US$110MSep 30, 2026
Bank of America1.42M0.73%US$93.4MSep 30, 2026
Schwab1.4M0.72%US$91.9MSep 30, 2026
Frontier Capital Management Co LLC1.39M0.71%US$91.6MSep 30, 2026
Goldman Sachs1.38M0.71%US$90.8MSep 30, 2026
Hood River Capital Management LLC1.32M0.68%US$87.1MSep 30, 2026
Laurion Capital Management LP1.29M0.66%US$84.8MSep 30, 2026
Morgan Stanley1.27M0.65%US$83.8MSep 30, 2026
Ameriprise1.26M0.64%US$82.6MSep 30, 2026
AllianceBernstein1.2M0.61%US$78.8MSep 30, 2026
Bellevue Group AG1.2M0.61%US$78.7MSep 30, 2026
Nomura1.11M0.57%US$72.8MSep 30, 2026
FIL Ltd1.03M0.53%US$67.8MSep 30, 2026
Jane Street1.01M0.52%US$66.4MSep 30, 2026
AQR Capital Management LLC984K0.51%US$64.8MSep 30, 2026
Northern Trust973K0.50%US$64MSep 30, 2026
GW&K Investment Management, LLC955K0.49%US$62.8MSep 30, 2026
Qube Research & Technologies Ltd891K0.46%US$58.7MSep 30, 2026
Deep Track Capital, LP886K0.45%US$58.3MSep 30, 2026
Renaissance Technologies857K0.44%US$56.4MSep 30, 2026
Summit Partners Public Asset Management, LLC820K0.42%US$54MSep 30, 2026
Principal777K0.40%US$51.2MSep 30, 2026
Susquehanna765K0.39%US$50.3MSep 30, 2026
Barclays755K0.39%US$49.7MSep 30, 2026

This page holds 50 of 458 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund5.6M2.9%US$417MJun 30, 2026
Vanguard Small-Cap Index Fund4.04M2.1%US$301MJun 30, 2026
Vanguard Health Care Fund3.16M1.6%US$253MJul 31, 2026
Vanguard Small-Cap Growth Index Fund2.33M1.2%US$174MJun 30, 2026
Vanguard Extended Market Index Fund1.97M1.0%US$147MJun 30, 2026
Janus Henderson Enterprise Fund1.91M0.98%US$142MJun 30, 2026
Vanguard Explorer Fund1.72M0.89%US$138MJul 31, 2026
Janus Henderson Global Life Sciences Fund1.59M0.82%US$118MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.48M0.76%US$110MJun 30, 2026
Invesco Discovery Fund1.32M0.68%US$87.1MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Biotechnology ETF1.2M0.62%US$89.2MJun 30, 2026
JPMorgan Mid Cap Growth Fund1.15M0.59%US$85.7MJun 30, 2026
Nomura Small Cap Core Fund1.13M0.58%US$74.6MMay 29, 2026
iShares Russell Mid-Cap Growth ETF940K0.48%US$70MJun 30, 2026
Fidelity Extended Market Index Fund872K0.45%US$57.8MMay 31, 2026
Vanguard Russell 2000 Index Fund815K0.42%US$54MMay 31, 2026
Schwab U.S. Small-Cap ETF815K0.42%US$54MMay 31, 2026
Janus Henderson Triton Fund814K0.42%US$60.7MJun 30, 2026
Select Biotechnology Portfolio707K0.36%US$46.9MMay 31, 2026
Franklin Dynatech Fund700K0.36%US$52.1MJun 30, 2026
iShares Russell Mid-Cap ETF694K0.36%US$51.7MJun 30, 2026
Hood River Small-Cap Growth Fund684K0.35%US$51MJun 30, 2026
SMALLCAP World Fund Inc681K0.35%US$50.7MJun 30, 2026
Lord Abbett Growth Leaders Fund662K0.34%US$53MJul 31, 2026
Fidelity Mid Cap Index Fund641K0.33%US$51.3MJul 31, 2026
Janus Henderson Venture Fund638K0.33%US$47.5MJun 30, 2026
Columbia Small Cap Growth Fund635K0.33%US$42.1MMay 31, 2026
iShares Russell 1000 Growth ETF610K0.31%US$45.4MJun 30, 2026
Hartford Core Equity Fund551K0.28%US$44.1MJul 31, 2026
Schwab U.S. Mid-Cap ETF459K0.24%US$30.4MMay 31, 2026
PRIMECAP Odyssey Aggressive Growth Fund449K0.23%US$35.9MJul 31, 2026
Eventide Healthcare & Life Sciences Fund437K0.22%US$32.6MJun 30, 2026
Vanguard Health Care Index Fund434K0.22%US$28.8MMay 31, 2026
AB Discovery Growth Fund, Inc.434K0.22%US$32.3MJun 30, 2026
Small Cap Growth Fund434K0.22%US$34.7MJul 31, 2026
Franklin Small Cap Growth Fund425K0.22%US$34MJul 31, 2026
Janus Henderson Global Select Fund417K0.21%US$31.1MJun 30, 2026
Vanguard Capital Opportunity Fund406K0.21%US$30.3MJun 30, 2026
Janus Henderson Research Fund391K0.20%US$29.1MJun 30, 2026
Columbia Acorn Fund390K0.20%US$29MJun 30, 2026
Fidelity Small Cap Growth Fund369K0.19%US$29.6MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.363K0.19%US$27.1MJun 30, 2026
Lord Abbett Developing Growth Fund Inc356K0.18%US$28.5MJul 31, 2026
Invesco Discovery Mid Cap Growth Fund342K0.18%US$27.4MJul 31, 2026
SmallCap Fund339K0.17%US$27.1MJul 31, 2026
Fidelity Total Market Index Fund320K0.16%US$21.2MMay 31, 2026
JNL/JPMorgan MidCap Growth Fund312K0.16%US$23.2MJun 30, 2026
Federated Hermes MDT Mid Cap Growth Fund309K0.16%US$24.8MJul 31, 2026
JNL/Invesco Small Cap Growth Fund285K0.15%US$21.3MJun 30, 2026
Voya Small Cap Growth Fund278K0.14%US$18.4MMay 31, 2026

This page holds 50 of 445 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Kumar Neil
Director, Officer: Chief Executive Officer
Sale8,500USD 78.35US$666KNov 19, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,500USD 79.29US$119KNov 19, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale4,490USD 76.99US$346KNov 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale30,490USD 77.83US$2.37MNov 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,277USD 76.99US$98,318Nov 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale8,723USD 77.83US$679KNov 18, 2026
Apuli Maricel
Officer: Chief Accounting Officer
Sale2,000USD 72.85US$146KOct 30, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale8,721USD 69.01US$602KSep 17, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,279USD 69.57US$88,980Sep 17, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale8,100USD 83.86US$679KAug 19, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,800USD 84.69US$152KAug 19, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale100USD 85.65US$8,565Aug 19, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,900USD 81.15US$154KAug 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale17,279USD 82.21US$1.42MAug 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale14,602USD 82.99US$1.21MAug 18, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,199USD 83.77US$100KAug 18, 2026
Apuli Maricel
Officer: Chief Accounting Officer
Sale2,000USD 80.06US$160KJul 30, 2026
Cook Jennifer E.
Director
Sale36,167USD 84.00US$3.04MJul 9, 2026
Cook Jennifer E.
Director
Sale112,422USD 90.00US$10.1MJul 9, 2026
Ellis Andrea
Director
Sale17,167USD 84.00US$1.44MJul 9, 2026
Cook Jennifer E.
Director
Sale37,167USD 70.00US$2.6MJun 24, 2026
Valantine Hannah
Director
Sale2,196USD 68.57US$151KJun 23, 2026
Cook Jennifer E.
Director
Sale2,196USD 68.57US$151KJun 23, 2026
Valantine Hannah
Director
Sale2,808USD 68.00US$191KJun 22, 2026
Cook Jennifer E.
Director
Sale88,737USD 66.62US$5.91MJun 15, 2026
Cook Jennifer E.
Director
Sale1,503USD 67.14US$101KJun 15, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale7,147USD 67.20US$480KJun 5, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale8,437USD 67.88US$573KJun 5, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale4,416USD 68.96US$305KJun 5, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale7,148USD 67.20US$480KJun 5, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale4,415USD 68.96US$304KJun 5, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale2,200USD 65.72US$145KJun 4, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale1,429USD 66.72US$95,343Jun 4, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale15,921USD 67.74US$1.08MJun 4, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale450USD 68.27US$30,722Jun 4, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale2,256USD 67.57US$152KMay 21, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale6,725USD 68.30US$459KMay 21, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale5,072USD 69.22US$351KMay 21, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale11,250USD 70.48US$793KMay 21, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale800USD 70.92US$56,736May 21, 2026
Trimarchi Thomas
Officer: President and CFO
Sale10,456USD 64.82US$678KMay 18, 2026
Trimarchi Thomas
Officer: President and CFO
Sale3,195USD 65.95US$211KMay 18, 2026
Scott Randal W.
Director
Sale6,200USD 66.69US$413KMay 15, 2026
Scott Randal W.
Director
Sale2,088USD 67.53US$141KMay 15, 2026
Scott Randal W.
Director
Sale1,512USD 68.23US$103KMay 15, 2026
Scott Randal W.
Director
Sale200USD 69.12US$13,824May 15, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale13,973USD 66.65US$931KMay 8, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale5,077USD 67.35US$342KMay 8, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale950USD 68.35US$64,932May 8, 2026
Kumar Neil
Director, Officer: Chief Executive Officer
Sale13,974USD 66.65US$931KMay 8, 2026

This page holds 50 of 65 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Farallon Capital Management, L.L.C.7.30%14.2MSep 30, 2026Schedule 13G
Janus Henderson Group PLC6.80%13.2MMar 31, 2026Schedule 13G
BlackRock, Inc.5.10%9.89MSep 30, 2026Schedule 13G
Viking Global Investors LP5.00%9.79MJul 9, 2026Schedule 13D
KKR Genetic Disorder L.P.4.20%8.26MAug 13, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Fred Hassan
Other companies: Recursion Pharmaceuticals, Inc. (Director · Since Oct 31, 2026); EyePoint, Inc. (Director · Since at least Sep 3, 2024); Cocrystal Pharma, Inc. (Director · Since at least Apr 20, 2023); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past)
Director · Since at least Aug 17, 2021
Brent Saunders
Other companies: Bausch + Lomb Corporation (Chairman of the Board and CEO, Director · Since at least Mar 6, 2023); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); SkinHealth Systems Inc. (Chairman · Since at least Sep 29, 2020); Cisco Systems, Inc. (Director · Mar 13, 2017 – Dec 8, 2022 · Past); Forest Laboratories Inc (CEO & President, Director · Aug 23, 2011 – Jun 30, 2014 · Past); Merck & Company, Inc. (Senior Vice President · May 19, 2006 – Nov 3, 2009 · Past)
Director · Jun 23, 2020 – Jun 22, 2022 · Past
Richard H. Scheller
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Alector, Inc. (Board Member · Since at least Feb 6, 2019); 23Andme Holding Co (Director · Jun 16, 2021 – Aug 26, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – May 20, 2021 · Past); Xenon Pharmaceuticals Inc. (Director · Mar 16, 2015 – Sep 16, 2019 · Past); Genentech Inc (EVP-RESEARCH · Jan 13, 2006 – Mar 26, 2009 · Past)
Director · Jun 27, 2019 – Feb 16, 2023 · Past
Charles Homcy
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Pliant Therapeutics, Inc. (Director · Jun 2, 2020 – Jun 29, 2021 · Past); Portola Pharmaceuticals Inc (Director · Jun 8, 2018 – Jan 2, 2019 · Past); Global Blood Therapeutics Inc (Director · Oct 3, 2017 – Jun 20, 2018 · Past)
Director · Since at least Jun 27, 2019
Ali J Satvat
Other companies: Coherus Oncology, Inc. (Director · Since at least Nov 6, 2014); Impel Neuropharma Inc (Director · Apr 22, 2021 – Apr 22, 2021 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jan 26, 2021 · Past); PRA Health Sciences Inc (Director · Nov 12, 2014 – Nov 12, 2014 · Past)
Director · Since at least Jun 27, 2019
Cameron Turtle
Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Mar 23, 2026); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Spyre Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 22, 2023); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past)
See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past
Frank McCormick
Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Olema Pharmaceuticals, Inc. (Director · Sep 18, 2020 – Nov 23, 2020 · Past); Aduro Biotech Inc (Director · Apr 14, 2015 – Jun 6, 2018 · Past); Exelixis, Inc. (Director · May 2, 2006 – Dec 6, 2013 · Past)
Director · Since at least Jun 27, 2019
Douglas A Dachille
Other companies: PNC Financial Services Group, Inc. (the) (Director · Since at least Feb 3, 2025); Equitable Holdings, Inc. (Director · Since at least Jan 15, 2025); American International Group, Inc. New (EVP and CIO · Sep 30, 2015 – Jun 29, 2021 · Past)
Director · Since at least Aug 17, 2021
Michael Henderson
Other companies: Apogee Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Board Member · Since at least Jun 22, 2023); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past)
Chief Business Officer · Jun 27, 2019 – Dec 15, 2020 · Past
Andrew Lo
Other companies: AbCellera Biologics Inc. (Director · Since at least Dec 3, 2021); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Sep 15, 2022 · Past)
Director · Since at least Jun 23, 2020
All 43 people
PersonSeat
Brian M Stolz
Other companies: Activision Blizzard Inc (Chief People Officer · May 31, 2016 – May 30, 2019 · Past); Bausch Health Companies Inc. (EVP, Administration & CHCO · Jul 20, 2013 – Jun 22, 2015 · Past)
Chief Operating Officer · Oct 9, 2019 – Aug 16, 2020 · Past
BridgeBio Pharma
Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 25, 2026); Sensei Biotherapeutics, Inc. (Chief Financial Officer · Jun 15, 2026 – Nov 5, 2026 · Past)
Executive Chairman by the Board of Directors · Since at least Apr 22, 2026
Hannah Valantine
Other companies: CareDx, Inc. (Director · Since at least Jul 1, 2021); Pacific Biosciences of California, Inc. (Director · Since at least Jun 16, 2021)
Director · Since at least Oct 23, 2021
James Momtazee
Other companies: Roivant Sciences Ltd. (Nominating and Governance Committee Member · Since at least Oct 1, 2021); PRA Health Sciences Inc (Director · Aug 13, 2019 – Jul 1, 2021 · Past)
Director · Since at least Jun 27, 2019
Jennifer E. Cook
Other companies: Denali Therapeutics Inc. (Director · Since at least May 31, 2024); Jazz Pharmaceuticals plc (Director · Since at least Dec 4, 2023)
Director · Since at least Jun 21, 2024
Neil Kumar
Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 27, 2026); BridgeBio Oncology Therapeutics, Inc. (Executive Chairman · Since at least Aug 11, 2025)
Chief Executive Officer, Director · Since at least Nov 16, 2023
Brian Stephenson
Other companies: Sensei Biotherapeutics, Inc. (Chief Financial Officer · Since at least Nov 5, 2026)
CFO and Treasurer · Nov 16, 2020 – Feb 25, 2025 · Past
Eric Aguiar
Other companies: Biomea Fusion, Inc. (Director · Since at least Jun 12, 2024)
Director · Since at least Jun 21, 2024
Pedro J. Beltran
Other companies: BridgeBio Oncology Therapeutics, Inc. (Chief Executive Officer · Since at least Aug 11, 2025)
Chief Executive Officer, Idan Elmelech as Chief Operating Officer · Since at least Apr 22, 2026
Randal W Scott
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026)
Director · Since at least Dec 1, 2023
Alex FidelerExecutive Director · Since at least Nov 4, 2026
Andrea EllisDirector · Since at least Aug 17, 2021
Brian KoertgenCTO · Since at least Nov 4, 2026
Bubba MurarkaExecutive Vice President · Since at least Mar 11, 2026
Caleb TrippChief Financial Officer · Feb 28, 2025 – Nov 4, 2026 · Past
Chinmay ShuklaSenior Vice President · Since at least Mar 30, 2026
ContactKaitlyn ReillyDirector · Since at least Oct 5, 2026
ContactKristen KelleherDirector · Since at least Oct 5, 2026
Daniel HongDirector · Since at least Nov 5, 2026
Daniel NickleChief Legal Officer · Since at least Nov 4, 2026
Hassan JaroudiDirector of Finance · Since at least Nov 4, 2026
Jeffrey ClarkeDirector · Since at least Nov 5, 2026
Kasia GosekChief Strategy Officer · Since at least Nov 4, 2026
Katherine ChangDirector · Since at least Nov 5, 2026
Lilian ZhangDirector of Research · Since at least Nov 4, 2026
Mandy RohrigVice President of Operations · Since at least Nov 4, 2026
Maricel ApuliChief Accounting Officer · Since at least Feb 19, 2025
Natalie HenchcliffeCOO · Since at least Nov 4, 2026
Reed AshfordDirector · Since at least Nov 5, 2026
Robert ChengExecutive Vice President · Since at least Nov 4, 2026
Ronald J DanielsDirector · Since at least Jun 17, 2021
Scott YahiroChief Commercial Officer · Since at least Nov 4, 2026
Thomas TrimarchiPresident and CFO · Since at least Jul 23, 2024

Open People

Log in to ask 6ix AI your own questions about BridgeBio Pharma, Inc.